e-Therapeutics Plc

GSK's Linerixibat Shows Significant Improvement in Cholestatic Pruritus for Primary Biliary Cholangitis Patients

14 days ago

• GSK's phase III GLISTEN trial demonstrates linerixibat significantly improves cholestatic pruritus (relentless itch) in patients with primary biliary cholangitis, addressing a major quality of life concern. • The late-breaking results were presented at the European Association for the Study of the Liver (EASL) Congress 2025, highlighting the potential for a new treatment option for this challenging symptom. • Primary biliary cholangitis is a chronic autoimmune liver disease that primarily affects women, with pruritus being one of the most debilitating symptoms impacting daily functioning and quality of life.

e-therapeutics' ETX-312 Shows Promise as Disease-Modifying MASH Treatment in Preclinical Studies

16 days ago

• e-therapeutics has presented new preclinical data demonstrating ETX-312, their GalOmic siRNA candidate, significantly improves NAFLD Activity Score in MASH mouse models both as monotherapy and in combination with other agents. • The experimental treatment showed comparable fibrosis progression reduction to GLP-1/GIP receptor agonists and FGF-21 analogues, with statistically significant reductions in hepatic collagen staining and circulating biomarkers. • ETX-312, currently in IND-enabling studies, is being developed with potential for quarterly subcutaneous dosing, with regulatory submission planned by the end of 2025.